Sign In
Section Navigation
Common TitleMARCH
Official Title Randomised, Open-label Study Evaluating Efficacy and Safety of Maraviroc as a Switch for Either NRTI or PI/r in HIV-1 Infected Individuals With Stable, Well‐Controlled Plasma HIV‐RNA While Taking Their First N(t)RTI + PI/r Regimen of cART
Phase Phase IV
ClinicalTrials.gov NCT01384682
Treatments
Maraviroc
Maraviroc Selzentry

Maraviroc

Tradename:SelzentryOther Names:MVCClass:Entry Inhibitors
Categories Switch/SimplificationDual TherapyTreatment-Experienced
Funding
IndustryViiV Healthcare
References
  • Pett SL, Amin J, Horban A, et al. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clin Infect Dis. 2016;63:122-32.
    [PubMed Abstract]
  • Tu E, Swenson LC, Land S, et al. Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study. J Clin Microbiol. 2013;51:2063-71.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.